AGRX vs. RNAZ, NBY, ONCO, CWBR, SXTP, CYTO, ARAV, CYCC, ARDS, and DRMA
Should you be buying Agile Therapeutics stock or one of its competitors? The main competitors of Agile Therapeutics include TransCode Therapeutics (RNAZ), NovaBay Pharmaceuticals (NBY), Onconetix (ONCO), CohBar (CWBR), 60 Degrees Pharmaceuticals (SXTP), Altamira Therapeutics (CYTO), Aravive (ARAV), Cyclacel Pharmaceuticals (CYCC), Aridis Pharmaceuticals (ARDS), and Dermata Therapeutics (DRMA). These companies are all part of the "pharmaceutical preparations" industry.
Agile Therapeutics (NASDAQ:AGRX) and TransCode Therapeutics (NASDAQ:RNAZ) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, analyst recommendations, community ranking, media sentiment, institutional ownership, risk, valuation, profitability and dividends.
Agile Therapeutics has a beta of 1.42, indicating that its share price is 42% more volatile than the S&P 500. Comparatively, TransCode Therapeutics has a beta of -0.35, indicating that its share price is 135% less volatile than the S&P 500.
Agile Therapeutics received 418 more outperform votes than TransCode Therapeutics when rated by MarketBeat users. However, 85.71% of users gave TransCode Therapeutics an outperform vote while only 67.73% of users gave Agile Therapeutics an outperform vote.
In the previous week, Agile Therapeutics had 2 more articles in the media than TransCode Therapeutics. MarketBeat recorded 3 mentions for Agile Therapeutics and 1 mentions for TransCode Therapeutics. Agile Therapeutics' average media sentiment score of 0.00 equaled TransCode Therapeutics'average media sentiment score.
Agile Therapeutics currently has a consensus price target of $8.50, indicating a potential upside of 1,925.26%. TransCode Therapeutics has a consensus price target of $480.00, indicating a potential upside of 105,743.44%. Given TransCode Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe TransCode Therapeutics is more favorable than Agile Therapeutics.
10.9% of Agile Therapeutics shares are held by institutional investors. 0.5% of Agile Therapeutics shares are held by insiders. Comparatively, 1.5% of TransCode Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
TransCode Therapeutics has a net margin of 0.00% compared to Agile Therapeutics' net margin of -73.83%. Agile Therapeutics' return on equity of 0.00% beat TransCode Therapeutics' return on equity.
Agile Therapeutics has higher revenue and earnings than TransCode Therapeutics. Agile Therapeutics is trading at a lower price-to-earnings ratio than TransCode Therapeutics, indicating that it is currently the more affordable of the two stocks.
Summary
Agile Therapeutics beats TransCode Therapeutics on 9 of the 15 factors compared between the two stocks.
Get Agile Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for AGRX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding AGRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Agile Therapeutics Competitors List
Related Companies and Tools
